利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

43 条记录 (耗时 0.041 秒)

    Serotonin and norepinephrine reuptake inhibitors and uses thereof
    4.
    发明授权
    Serotonin and norepinephrine reuptake inhibitors and uses thereof 失效
    5-羟色胺和去甲肾上腺素再摄取抑制剂及其用途

    公开(公告)号：US07687520B2

    公开(公告)日：2010-03-30

    申请号：US11485693

    申请日：2006-07-13

    申请人： Syed M. Shah ,  Mahdi B. Fawzi ,  Panolil Raveendranath ,  Eric C. Ehrnsperger

    发明人： Syed M. Shah ,  Mahdi B. Fawzi ,  Panolil Raveendranath ,  Eric C. Ehrnsperger

    IPC分类号： A61K31/445 ,  C07D211/44

    CPC分类号： C07D211/44

    摘要： Selective dual serotonin and norepinephrine reuptake inhibitors are provided. These compounds have a lower side-effect profile and are useful in compositions and products for use in treatment of a variety of conditions including depression, fibromyalgia, anxiety, panic disorder, agorophobia, post traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, Gilles de la Tourette Syndrome, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction, borderline personality disorder, fibromyalgia syndrome, diabetic neuropathic pain, chronic fatigue syndrome, pain, Shy Drager syndrome, Raynaud's syndrome, Parkinson's Disease, and epilepsy.

    摘要翻译： 提供选择性双重5-羟色胺和去甲肾上腺素再摄取抑制剂。 这些化合物具有较低的副作用特征，并且可用于治疗各种病症的组合物和产品，包括抑郁症，纤维肌痛，焦虑症，惊恐障碍，广泛性恐惧症，创伤后应激障碍，经前焦虑障碍，注意力缺陷障碍， 强迫症，社会焦虑症，广泛性焦虑症，自闭症，精神分裂症，肥胖症，神经性厌食症，神经性贪食症，杜氏综合征，血管舒缩性潮红，可卡因和酒精成瘾，性功能障碍，边缘性人格障碍，纤维肌痛综合征，糖尿病性神经病变 疼痛，慢性疲劳综合征，疼痛，Shie Drager综合征，雷诺综合征，帕金森病和癫痫。

    Serotonin and norepinephrine reuptake inhibitor and uses thereof
    5.
    发明授权
    Serotonin and norepinephrine reuptake inhibitor and uses thereof 失效
    5-羟色胺和去甲肾上腺素再摄取抑制剂及其应用

    公开(公告)号：US07595340B2

    公开(公告)日：2009-09-29

    申请号：US11486336

    申请日：2006-07-13

    申请人： Syed M. Shah ,  Mahdi B. Fawzi ,  Eric C. Ehrnsperger ,  Panolil Raveendranath

    发明人： Syed M. Shah ,  Mahdi B. Fawzi ,  Eric C. Ehrnsperger ,  Panolil Raveendranath

    IPC分类号： A61K31/35 ,  C07D309/10

    CPC分类号： C07D309/10 ,  A61K9/20 ,  A61K9/48

    摘要： Selective dual serotonin and norepinephrine reuptake inhibitors are provided. These compounds have a lower side-effect profile and are useful in compositions and products for use in treatment of a variety of conditions including depression, fibromyalgia, anxiety, panic disorder, agoraphobia, post traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, Gilles de la Tourette Syndrome, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction, borderline personality disorder, fibromyalgia syndrome, diabetic neuropathic pain, chronic fatigue syndrome, pain, Shy Drager syndrome, Raynaud's syndrome, Parkinson's Disease, and epilepsy.

    摘要翻译： 提供选择性双重5-羟色胺和去甲肾上腺素再摄取抑制剂。 这些化合物具有较低的副作用特征，并且可用于治疗各种病症的组合物和产品，包括抑郁症，纤维肌痛，焦虑症，惊恐障碍，广场恐怖症，创伤后应激障碍，经前期焦虑障碍，注意力缺陷障碍， 强迫症，社会焦虑症，广泛性焦虑症，自闭症，精神分裂症，肥胖症，神经性厌食症，神经性贪食症，杜氏综合征，血管舒缩性潮红，可卡因和酒精成瘾，性功能障碍，边缘性人格障碍，纤维肌痛综合征，糖尿病性神经病变 疼痛，慢性疲劳综合征，疼痛，Shie Drager综合征，雷诺综合征，帕金森病和癫痫。

    Solid dosage formulations
    7.
    发明申请
    Solid dosage formulations 审中-公开
    固体剂型

    公开(公告)号：US20070259041A1

    公开(公告)日：2007-11-08

    申请号：US11799870

    申请日：2007-05-03

    申请人： Christopher Richard Diorio ,  Eric Ehrnsperger ,  Syed M. Shah

    发明人： Christopher Richard Diorio ,  Eric Ehrnsperger ,  Syed M. Shah

    IPC分类号： A61K31/137 ,  A61K9/24

    CPC分类号： A61K31/277 ,  A61K9/2054 ,  A61K9/2846 ,  A61K9/2866 ,  A61K31/137

    摘要： Solid dosage formulations are provided for a compound having the formula: wherein R2 is Cl, F, Br, CH3, CF3, SCH3, NHCH3, NO2, CN, OH, OC1—C6 alkyl, or substituted OC1—C6 alkyl, or a prodrug or a pharmaceutically acceptable salt thereof. Formulations for tablets and multiparticulates containing a compound according to the above formula, a rate controlling component, and a binder are described, including formulations containing a seal coating, release rate controlling coating, and/or enteric coating. Pharmaceutical uses and kits thereof are also described.

    摘要翻译： 提供了具有下式的化合物的固体剂型：其中R 2是Cl，F，Br，CH 3，CF 3，SCH NH 3，NH 2，NO 2，CN，OH，OC 1 -C 6， 或其取代的OC 1 -C 6烷基，或其前药或药学上可接受的盐。 描述了包含根据上式的化合物，速率控制组分和粘合剂的片剂和多颗粒的制剂，包括含有密封涂层，释放速率控制涂层和/或肠溶衣的制剂。 还描述了药物用途及其试剂盒。

    Controlled-release melatonin compositions and related methods
    9.
    发明授权
    Controlled-release melatonin compositions and related methods 有权
    控制释放褪黑素组合物及相关方法

    公开(公告)号：US08691275B2

    公开(公告)日：2014-04-08

    申请号：US13359638

    申请日：2012-01-27

    申请人： Syed M. Shah ,  Daniel Hassan

    发明人： Syed M. Shah ,  Daniel Hassan

    IPC分类号： A61K9/14 ,  A61K31/4045 ,  A61P5/00

    CPC分类号： A61K31/4045 ,  A61K9/0053 ,  A61K9/2013 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/2077 ,  A61K9/28

    摘要： This disclosure relates to controlled-release melatonin compositions and related methods. In one embodiment, a controlled-release medicament composition comprises melatonin dispersed in a controlled melatonin release portion comprising a polymer matrix, the polymer matrix adapted to encapsulate the melatonin in a melatonin solubility enhancing pH environment and to maintain the melatonin solubility enhancing pH environment when the composition is located in a melatonin solubility diminishing pH environment for allowing an effective amount of melatonin to be released into the melatonin solubility diminishing pH environment.

    摘要翻译： 本公开涉及控释褪黑激素组合物和相关方法。 在一个实施方案中，控释药物组合物包含分散在包含聚合物基质的受控褪黑激素释放部分中的褪黑素，所述聚合物基质适于将褪黑激素包封在褪黑激素溶解度增强pH环境中并且当所述褪黑激素溶解度增强pH环境时， 组合物位于褪黑素溶解度降低的pH环境中，以允许有效量的褪黑激素释放到褪黑激素溶解度降低的pH环境中。

    Method of providing coginition enhancement with 5&agr;-pregnan-3&bgr;-ol-20-one sulfate
    10.
    发明授权
    Method of providing coginition enhancement with 5&agr;-pregnan-3&bgr;-ol-20-one sulfate 失效
    用5α-孕烷-3β-ol-20-一硫酸盐提供精制增强的方法

    公开(公告)号：US06395723B2

    公开(公告)日：2002-05-28

    申请号：US09971159

    申请日：2001-10-04

    申请人： Michael Z. Kagan ,  Syed M. Shah

    发明人： Michael Z. Kagan ,  Syed M. Shah

    IPC分类号： A61K357

    CPC分类号： A61K31/57

    摘要： This invention provides a method of providing progestational therapy to a mammal in need thereof which comprises administering a progestationally effective amount of a pharmaceutically acceptable salt of 5&agr;-pregnan-3&bgr;-ol-20-one 3-sulfate ester to said mammal.

    摘要翻译： 本发明提供了向有需要的哺乳动物提供孕激素治疗的方法，该方法包括向所述哺乳动物施用孕激素有效量的5α-孕烷-3β-20-酮-3-硫酸酯的药学上可接受的盐。